Meeting Icon
The first-in-class humanized monoclonal antibody crizanlizumab reduced the rate of sickle cell-related pain crises, compared with placebo. Dr. Ataga discusses results of the SUSTAIN trial.
Kenneth Ataga, MD: Crizanlizumab: A New Option for Managing Sickle Cell-Related Pain Crises?
